Liquid Biopsy Wins Every Discordant Case Against Tumor-Informed Tests in Head-to-Head Cancer Monitoring Study

A tissue-free liquid biopsy test has demonstrated equivalent or superior performance to tumor-informed ctDNA assays in tracking cancer treatment response, according to a peer-reviewed study that could reshape how oncologists monitor disease without requiring upfront tumor sequencing.

The retrospective real-world comparison, published in The Journal of Liquid Biopsy, evaluated 169 paired samples from 61 patients with advanced cancer using BillionToOne's Northstar Response alongside tumor-informed comparator assays. The study found 94% concordance in tumor burden direction across 71 sequential samples collected within seven days, with a conditional R² of 0.97 after patient-specific baseline normalization.

Perfect Record in Divergent Cases

The most striking finding emerged in the 4 of 71 cases where the two approaches disagreed. In every discordant instance, Northstar Response aligned with ground truth from imaging and biopsy while the tumor-informed assay produced false-positives or false-negatives, according to the study data.

One clinical example highlighted the test's ability to detect tumor evolution: Northstar Response identified disease progression in an advanced breast cancer patient whose hormone receptor status had converted since the original biopsy—a change the tumor-informed approach missed because it relied on the outdated tissue profile.

The technology utilizes patented Quantitative Counting Templates (QCT™) for single-molecule counting of methylation-based ctDNA markers, eliminating the need for upfront tumor sequencing that can delay monitoring initiation by weeks.

Workflow Advantages in Clinical Practice

For oncologists, the tissue-free approach addresses a persistent clinical challenge: tracking cancer when biopsies are unavailable, inadequate, or anatomically difficult to obtain. Traditional tumor-informed assays require sufficient tissue for sequencing before blood monitoring can begin, creating delays and excluding patients whose tumor samples are exhausted or inaccessible.

"Northstar Response offers treatment monitoring without tissue dependency, potentially accelerating molecular monitoring initiation by weeks," according to study researchers including Dr. Vaia Florou, Associate Professor in the Division of Oncology at Huntsman Cancer Institute, University of Utah, and Dr. Allen Chen, VP of Oncology Clinical Development at BillionToOne.

The validation positions the Menlo Park, California-based company's approach as a direct competitor to established tumor-informed platforms in the liquid biopsy market, with potential advantages in turnaround time and applicability to cases where tissue availability limits current options.

Market and Regulatory Context

Northstar Response is offered as a laboratory-developed test (LDT) performed in a CLIA-certified, CAP-accredited laboratory. The test is not FDA cleared or approved, and its LDT regulatory status means coverage and reimbursement pathways remain uncertain for patients.

The head-to-head data arrives as the liquid biopsy market expands rapidly, with tissue-free approaches potentially offering workflow efficiencies that could shift competitive dynamics toward tumor-agnostic methylation-based monitoring. The ability to track tumor evolution under treatment pressure—including receptor conversion and clonal selection that fixed-timepoint tissue sequencing may miss—represents a particular advantage for longitudinal disease monitoring.

BillionToOne (Nasdaq: BLLN) conducted the study across 61 patients with advanced cancer, providing real-world evidence for the methylation-based platform's performance against the current standard in cancer treatment response monitoring.

Sources

1. BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds — StockTitan.net